Real World Evidence
(Non-Interventional Studies/Phase IV)

Your global partner for quality evidence and reliable outcomes

Every research question is unique, and so is every study. TFS HealthScience works with you to select the best methodologies for your non-interventional and late phase studies. We access a variety of data sources, tools, technologies, and sites for your unique project to extract the best outcome.

Global Real World Evidence:
introducing

TFS ReAL combines a strong scientific focus with local expertise and global capabilities. We have a cross-functional expert team including scientific, epidemiological, medical, statistical, technological, and operational professionals.

Our capabilities include four main pillars:

  • RWD Sources

  • e-Digital

  • Analytics

  • Life Science

RWD Sources

Enabling RWD access:

  • Best Public/Private RWD for:

    – Feasibility / I/E criteria– Patient recruitment

    – Historical cohorts– Observational studies

  • Local expertise (Nordic registries, NIS approval tips)

e-Digital

Digital RWE platform:

  • Integrated EDC - eSources:

    – eConsent– ePRO / eDiary
    – eRetention– e(remote) Visits

    – eHealth:
    – Wearables / biosensors– Passive smartphone data

Analytics

Best-in-class evidence:

  • Confounding adjustment (PSM, IPTW)

  • Predictive analytics (multivariate,
    machine learning, AI)

  • Unstructured data processing (NLP)

  • OMOP-OHDSI expertise

Life Science

RWE intelligence:

  • Study design: TFS-RWE Algorithm

  • Protocol optimization: endpoints, sample
    size, bias & confounding

  • Increased ROI: commercial value

  • Expertise biomarkers/genomics

  • Increased impact factor

TFS RWE at a glance

  • Over

    50%

    Operations staff with RWE experience
  • Nearly

    250

    Studies
  • Nearly

    100,000

    Patients in RWE and Phase IV Studies
  • Nearly

    7,000

    Sites
  • Studies performed in

    19

    Countries
  • Over

    25

    Clients
  • Over

    300

    Healthcare data sources in the
    EU and NA
  • Over

    60

    Transnational databases
  • Over

    20

    Ongoing collaborations with data owners

Virtual studies a solution in time of COVID-19

The COVID-19 pandemic has placed a spotlight on the necessity of virtual trials. In particular, real-world evidence studies are ideally suited for virtual or decentralized studies due to their typically large number of geographically dispersed participants and longer observation periods. Thankfully, there is an increasing spectrum of validated systems and devices to gather endpoints for clinical trials across all therapeutic areas.

Learn more